Duluth, Georgia
Boehringer Ingelheim Animal Health employs about
Search
Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Breathless Ballad
Breathless Ballad
Our Responsibility
Our Responsibility
Innovation in CardioMetabolic Disease Research
Innovation in CardioMetabolic Disease Research
Sant Cugat del Vallès (Barcelona)
Boehringer Ingelheim settled in Spain in 1952. For almost 70 years, t
Driving Innovation through Diversity & Inclusion
Driving innovation through diversity and inclusion. Inclusive leaders and an inclusive organisation allow diversity to flourish. Diversity is the mix. Inclusion is making the mix work.
Retinal Diseases
Retinal Diseases
Heart Diseases
Heart Diseases
More Potential
More Potential
Fremont, California
Boehringer Ingelheim’s Fremont, California facility in the San Francisco Bay
Niha Agarwalla
My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
Cancer
Cancer
Patient Centricity
Patient Centricity
Interchangeable Biosimilar Now on Express Scripts® Formulary
Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary
Purpose Hero Video
Begin a career with purpose and explore careers at Boehringer Ingelheim.
Championing minds for generations both in and out of the workplace
Boehringer Ingelheim is now certified for Mental Health America’s (MHA) Bell Seal for Workplace Mental Health.
Horses
Horses
Koropi
With its presence in Greece of more than a half century, Boehringer Ingelheim inaugurated the production facility in Koropi in 1975.
Hannah Bussmann
Get an inside view of life at Boehringer Ingelheim with Hannah Bussmann.
Leticia develops product medical strategies
Leticia develops product medical strategies at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
Top-line Phase II Data for treatment of MASH
Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).
Venu Thatikonda
An in-depth look into working life at Boehringer Ingelheim with Venu Thatikonda.